CO2017012454A2 - Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia - Google Patents
Secuencias de uricasa adecuadas para el tratamiento de hiperuricemiaInfo
- Publication number
- CO2017012454A2 CO2017012454A2 CONC2017/0012454A CO2017012454A CO2017012454A2 CO 2017012454 A2 CO2017012454 A2 CO 2017012454A2 CO 2017012454 A CO2017012454 A CO 2017012454A CO 2017012454 A2 CO2017012454 A2 CO 2017012454A2
- Authority
- CO
- Colombia
- Prior art keywords
- hyperuricemia
- treatment
- sequences suitable
- uricase
- uricase sequences
- Prior art date
Links
- 201000001431 Hyperuricemia Diseases 0.000 title abstract 2
- 108010092464 Urate Oxidase Proteins 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000011443 conventional therapy Methods 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12N9/0048—Uricase (1.7.3.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562162280P | 2015-05-15 | 2015-05-15 | |
| PCT/US2016/032415 WO2016187026A1 (en) | 2015-05-15 | 2016-05-13 | Improved uricase sequences and methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017012454A2 true CO2017012454A2 (es) | 2018-04-30 |
Family
ID=57320301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0012454A CO2017012454A2 (es) | 2015-05-15 | 2017-12-01 | Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11098289B2 (enExample) |
| EP (1) | EP3294322A4 (enExample) |
| JP (2) | JP2018515101A (enExample) |
| KR (1) | KR20180002828A (enExample) |
| CN (1) | CN107614007B (enExample) |
| AU (2) | AU2016265677B2 (enExample) |
| BR (1) | BR112017024212A2 (enExample) |
| CA (1) | CA2984926A1 (enExample) |
| CL (1) | CL2017002774A1 (enExample) |
| CO (1) | CO2017012454A2 (enExample) |
| HK (1) | HK1252542A1 (enExample) |
| IL (1) | IL255403A0 (enExample) |
| MX (1) | MX2017014547A (enExample) |
| MY (1) | MY190411A (enExample) |
| RU (1) | RU2752497C2 (enExample) |
| SG (2) | SG11201708759YA (enExample) |
| WO (1) | WO2016187026A1 (enExample) |
| ZA (1) | ZA201708507B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016187026A1 (en) | 2015-05-15 | 2016-11-24 | Medimmune, Llc | Improved uricase sequences and methods of treatment |
| CN106554948B (zh) * | 2015-09-29 | 2019-06-25 | 上海生物制品研究所有限责任公司 | 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用 |
| CN112410313A (zh) * | 2019-08-20 | 2021-02-26 | 中国科学院上海药物研究所 | 一种高热稳定性尿酸酶及其应用 |
| CN112646790A (zh) * | 2019-10-11 | 2021-04-13 | 上海君实生物医药科技股份有限公司 | 改进的尿酸酶及其用于治疗高尿酸血症的方法 |
| CN114746546B (zh) * | 2019-10-29 | 2024-09-03 | 西湖生物医药科技(杭州)有限公司 | 工程化红细胞用于治疗痛风和高尿酸血症 |
| KR20230059777A (ko) | 2020-09-25 | 2023-05-03 | 주식회사 프로앱텍 | 요산산화효소-알부민 접합체, 그 제조방법 및 용도 |
| US20230374471A1 (en) * | 2020-10-13 | 2023-11-23 | University Of Florida Research Foundation, Incorporated | Self-assembling uricase fusion peptides |
| JP7833461B2 (ja) | 2020-11-03 | 2026-03-19 | プロタリクス リミテッド | 修飾ウリカーゼ及びその使用 |
| CN114438048B (zh) * | 2020-11-05 | 2024-10-22 | 重庆派金生物科技有限公司 | 尿酸氧化酶制剂及其应用 |
| WO2022214086A1 (zh) * | 2021-04-09 | 2022-10-13 | 上海君实生物医药科技股份有限公司 | 尿酸酶、其药物组合物及其用途 |
| WO2023282556A1 (ko) * | 2021-07-08 | 2023-01-12 | 주식회사 프로앱텍 | Arthrobacter globiformis 유래 요산산화효소-알부민 접합체, 그 제조방법 및 그 용도 |
| KR20240083169A (ko) * | 2021-09-23 | 2024-06-11 | 주식회사 프로앱텍 | Apn 그룹을 포함하는 링커 및 이를 이용하여 제조된 기능성 폴리펩티드 변이체-알부민 컨쥬게이트 |
| US20250241999A1 (en) * | 2021-10-15 | 2025-07-31 | Georgia State University Research Foundation, Inc. | Delivery of therapeutic recombinant uricase using nanoparticles |
| US12703857B2 (en) | 2023-02-02 | 2026-08-11 | Protalix Ltd. | Methods of treating diseases associated with elevated uric acid |
| WO2026102031A1 (en) * | 2024-11-06 | 2026-05-15 | Insmed Incorporated | Pasylated uricase variants and methods of use thereof |
| CN119752761B (zh) * | 2025-03-07 | 2025-06-17 | 北京化工大学 | 一种高产heparosan的基因工程菌及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09154581A (ja) * | 1995-12-05 | 1997-06-17 | Asahi Chem Ind Co Ltd | ウリカーゼを生産する実質上純粋な微生物 |
| PL202799B1 (pl) | 1998-08-06 | 2009-07-31 | Mountain View Pharmaceuticals | Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza |
| ATE298251T1 (de) * | 1998-08-06 | 2005-07-15 | Mountain View Pharmaceuticals | Peg-uricase konjugate und verwendung davon |
| US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| US7056713B1 (en) | 1998-08-06 | 2006-06-06 | Duke University | Urate oxidase |
| AU775937B2 (en) * | 1999-01-14 | 2004-08-19 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| US6913915B2 (en) * | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
| MX2007012548A (es) * | 2005-04-11 | 2008-03-11 | Savient Pharmaceuticals Inc | Formas variantes de urato oxidasa y uso de las mismas. |
| KR20080009111A (ko) * | 2005-04-11 | 2008-01-24 | 새비언트 파마수티컬즈 인크. | 유레이트 옥시다아제의 변이형 및 이의 용도 |
| US8148123B2 (en) | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
| ES2716864T3 (es) | 2007-06-06 | 2019-06-17 | Monsanto Technology Llc | Genes y usos para la mejora de plantas |
| US20130305398A1 (en) * | 2012-02-16 | 2013-11-14 | Marie Coffin | Genes and uses for plant enhacement |
| JP2012531596A (ja) | 2009-06-25 | 2012-12-10 | サヴィエント・ファーマシューティカルズ・インコーポレイテッド | Ｐｅｇ化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット |
| CN103184209B (zh) * | 2011-12-27 | 2015-09-16 | 拜奥生物科技（上海）有限公司 | 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用 |
| WO2016187026A1 (en) | 2015-05-15 | 2016-11-24 | Medimmune, Llc | Improved uricase sequences and methods of treatment |
-
2016
- 2016-05-13 WO PCT/US2016/032415 patent/WO2016187026A1/en not_active Ceased
- 2016-05-13 RU RU2017143580A patent/RU2752497C2/ru active
- 2016-05-13 MY MYPI2017704267A patent/MY190411A/en unknown
- 2016-05-13 AU AU2016265677A patent/AU2016265677B2/en not_active Ceased
- 2016-05-13 CA CA2984926A patent/CA2984926A1/en active Pending
- 2016-05-13 EP EP16797021.9A patent/EP3294322A4/en not_active Withdrawn
- 2016-05-13 KR KR1020177035108A patent/KR20180002828A/ko not_active Ceased
- 2016-05-13 SG SG11201708759YA patent/SG11201708759YA/en unknown
- 2016-05-13 SG SG10201910522TA patent/SG10201910522TA/en unknown
- 2016-05-13 JP JP2017559314A patent/JP2018515101A/ja active Pending
- 2016-05-13 MX MX2017014547A patent/MX2017014547A/es unknown
- 2016-05-13 US US15/573,993 patent/US11098289B2/en active Active
- 2016-05-13 HK HK18111855.1A patent/HK1252542A1/zh unknown
- 2016-05-13 CN CN201680027432.9A patent/CN107614007B/zh not_active Expired - Fee Related
- 2016-05-13 BR BR112017024212A patent/BR112017024212A2/pt not_active IP Right Cessation
-
2017
- 2017-11-02 IL IL255403A patent/IL255403A0/en unknown
- 2017-11-03 CL CL2017002774A patent/CL2017002774A1/es unknown
- 2017-12-01 CO CONC2017/0012454A patent/CO2017012454A2/es unknown
- 2017-12-14 ZA ZA2017/08507A patent/ZA201708507B/en unknown
-
2018
- 2018-10-23 US US16/167,765 patent/US10883087B2/en active Active
-
2020
- 2020-11-18 US US16/951,764 patent/US20210254024A1/en not_active Abandoned
-
2021
- 2021-08-06 JP JP2021130287A patent/JP2021184733A/ja active Pending
-
2022
- 2022-01-10 AU AU2022200104A patent/AU2022200104A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US11098289B2 (en) | 2021-08-24 |
| US10883087B2 (en) | 2021-01-05 |
| HK1252542A1 (zh) | 2019-05-31 |
| CL2017002774A1 (es) | 2018-04-06 |
| MY190411A (en) | 2022-04-21 |
| AU2016265677B2 (en) | 2021-12-09 |
| EP3294322A1 (en) | 2018-03-21 |
| JP2021184733A (ja) | 2021-12-09 |
| AU2016265677A1 (en) | 2018-01-04 |
| JP2018515101A (ja) | 2018-06-14 |
| RU2017143580A3 (enExample) | 2019-12-16 |
| US20190048327A1 (en) | 2019-02-14 |
| SG11201708759YA (en) | 2017-11-29 |
| CA2984926A1 (en) | 2016-11-24 |
| CN107614007B (zh) | 2022-03-25 |
| US20180258406A1 (en) | 2018-09-13 |
| IL255403A0 (en) | 2017-12-31 |
| SG10201910522TA (en) | 2020-01-30 |
| WO2016187026A1 (en) | 2016-11-24 |
| BR112017024212A2 (pt) | 2018-07-17 |
| AU2022200104A1 (en) | 2022-02-03 |
| RU2752497C2 (ru) | 2021-07-28 |
| MX2017014547A (es) | 2018-03-15 |
| CN107614007A (zh) | 2018-01-19 |
| KR20180002828A (ko) | 2018-01-08 |
| US20210254024A1 (en) | 2021-08-19 |
| EP3294322A4 (en) | 2018-12-12 |
| RU2017143580A (ru) | 2019-06-17 |
| ZA201708507B (en) | 2018-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4631970A3 (en) | Nucleic acid molecules and uses thereof | |
| CY1124742T1 (el) | 4'-φθορο-νουκλεοσιδια, 4'-φθορο-νουκλοεοτιδια και αναλογα αυτων για τη θεραπευτικη αγωγη toy hcv | |
| CY1121348T1 (el) | Mrna θεραπεια για την θεραπευτικη αγωγη οφθαλμικων ασθενειων | |
| ZA202004764B (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
| SA519401435B1 (ar) | مركبات حلقية ثنائية النيوكليوتيد | |
| MX2018014573A (es) | Vacuna contra el virus del zika. | |
| CL2019000732A1 (es) | Tratamiento avv de la enfermedad de huntington. | |
| WO2018115507A3 (en) | Henipavirus vaccine | |
| CR20170359A (es) | Oligómetros antisentido de tau y usos de estos | |
| MY190411A (en) | Improved uricase sequences and methods of treatment | |
| EA201590703A1 (ru) | Ингибиторы mek при лечении вирусных заболеваний | |
| EA201890815A1 (ru) | Аминокислотные композиции с модифицированным высвобождением для перорального введения | |
| ES2694667T3 (es) | Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato | |
| PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
| CU20210061A7 (es) | Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer | |
| PY2188555A (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 | |
| EA202090260A1 (ru) | Средства и способы для генотерапии aav у человека | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
| PY2285025A (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 | |
| EA201690966A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
| MX2017013480A (es) | Composicion farmaceutica para tratar y/o prevenir el cancer. | |
| EA201591095A1 (ru) | Белок slurp-1 для применения в лечении глазных болезней | |
| BR112018073300A2 (pt) | métodos para tratamento de doenças associadas com as células ilc3 | |
| BR112017000146A2 (pt) | micro-organismo recombinante do gênero escherichia produzindo ácido quinolínico, e método de produção de ácido quinolínico | |
| EA202090336A1 (ru) | Соединения, их соли и способы лечения заболеваний |